Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma

Annals of Oncology

Volumn 15, Issue 12, 2004, Pages 1805-1809

  Toffoli, G ^a   Corona, G ^a   Cattarossi, G ^a   Boiocchi, G ^a   Di Gennaro, G ^a   Tirelli, U ^a   Vaccher, E ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

CHOP; Doxorubicin; HAART; HIV; Interactions; Pharmacokinetics

Indexed keywords

CYCLOPHOSPHAMIDE; DIDANOSINE; DOXORUBICIN; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PREDNISONE; SAQUINAVIR; STAVUDINE; VINCRISTINE; ZIDOVUDINE;

ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION TEST; LEUKOPENIA; LIVER FUNCTION TEST; MALE; MUCOSA INFLAMMATION; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AREA UNDER CURVE; CROSS-OVER STUDIES; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; LYMPHOMA, AIDS-RELATED; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISONE; VINCRISTINE;

EID: 10944255107     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh464     Document Type: Article

References (20)

1. Kirk O, Pedersen C, Cozzi-Lepri A et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001; 98: 3406-3412.
2. Silvestris N, Crucitta E, Lorusso V et al. AIDS-related non-Hodgkin's lymphoma: clinico-pathological characteristics and therapeutic strategies (review). Int J Oncol 2002; 20: 611-615.
3. Ratner L, Lee J, Tang S et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001; 19: 2171-2178.
4. Vaccher E, Spina M, di Gennaro G et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001; 91: 155-163.
5. Sparano JA, Wiernik PH, Hu X et al. Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma. Med Oncol 1998; 15: 50-57.
6. Flexner C. HIV-protease inhibitors. N Engl J Med 1998; 338: 1281-1292.
7. Gutmann H, Fricker G, Drewe J et al. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 1999; 56: 383-389.
8. Deng L, Tatebe S, Lin-Lee YC et al. MDR and MRP gene families as cellular determinant factors for resistance to clinical anticancer agents. Cancer Treat Res 2002; 112: 49-66.
9. Fichtenbaum CJ, Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet 2003; 41: 1195-1211.
10. Fumagalli L, Zucchetti M, Parisi I et al. The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma. Cancer Chemother Pharmacol 2000; 45: 495-501.
11. Nannan PV, Hoetelmans RM, van Heeswijk RP et al. Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma-drug-drug interactions with protease inhibitors and a non-nucleoside reverse transcriptase inhibitor: a case report study. Cancer Chemother Pharmacol 1999; 43: 516-519.
12. Tirelli U, Spina M, Gaidano G et al. Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. AIDS 2000; 14: 1675-1688.
13. World Health Organisation. WHO Handbook for reporting results of cancer treatment. WHO offset publication No. 48. Geneva: World Health Organisation 1979.
14. Moro E, Bellotti V, Jannuzzo MG et al. High-performance liquid chromatographic method for pharmacokinetic studies on the new anthracycline 4-demethoxydaunorubicin and its 13-dihydro derivative. J Chromatogr 1983; 274: 281-287.
15. Washington CB, Duran GE, Man MC et al. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19: 203-209.
16. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92: 1295-1302.
17. Speth PA, van Hoesel QG, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 1988; 15: 15-31.
18. Merry C, Barry MG, Mulcahy F et al. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. AIDS 1998; 12: 1163-1167.
19. Merry C, Barry MG, Mulcahy F et al. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS 1997; 11: F117-F120.
20. Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991; 66: 85-94.